Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EBMT 2021 | T-Cell lymphoma: implications of interleukin-10 loss

Ali Bazarbachi • 12 Mar 2021
EBMT 2021
Lymphoma Non-Hodgkin Lymphoma T-Cell Lymphoma Antibodies Arsenic trioxide Interferon

Ali Bazarbachi, MD, PhD, American University of Beirut Medical Center, Beirut, Lebanon, discusses the challenges of treating adult T-cell leukemia/lymphoma (TCL). Prof. Bazarbachi outlines the results of a study that demonstrated that arsenic trioxide (AS) and interferon-α (IFNα)-induced abrogation of leukemia-initiating cell activity requires IL-10 expression shutoff in patients with adult TCL. This loss of IL-10 results in increased production of inflammatory cytokines, resulting in innate immunity-mediated clearance of Tax-driven leukemic cells. This interview took place during the 47th Annual Meeting of the European Group for Blood and Marrow Transplantation (EBMT) 2021.

More from Ali Bazarbachi

6:52
Somatic mutations that impact alloSCT outcomes in patients with AML
Ali Bazarbachi • 19 Dec 2023
8:11
Improvements over time in elderly patients with AML treated with alloSCT: an EBMT Registry study
Ali Bazarbachi • 19 Dec 2023
11:16
Latest advancements in alloHSCT for ALL
Ali Bazarbachi • 21 Mar 2022
9:06
Advances in the management of R/R Hodgkin lymphoma
Ali Bazarbachi • 28 Sep 2021

Related Videos

3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
2:11
The role of CAR-T therapy for lymphoma in 2024: expert session highlights
Sridhar Chaganti • 16 Apr 2024
1:32
Promising novel immunotherapeutic approaches in lymphoma
Gloria Iacoboni • 15 Apr 2024
3:03
AlloSCT outcomes after immunotherapy vs chemotherapy in patients with R/R NHL: a retrospective study
Jacopo Mariotti • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals